Article
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
Expanded Access Program for recombinant BCG launches at first US site
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
House passes bill that includes 57% budget cut to medical research programs
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
Phase 3 trial launches ArteraAI Prostate Test for treatment selection
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC